新聞及媒體 News and Media

PenTide Therapeutics was pleased to be selected to present at the Global Healthcare Innovation Summit (GHIS) 2026 Greater Bay Area (GBA) Special Roadshow, held on 26 October 2026 at the Grand Hyatt Hong Kong.

During the roadshow, PenTide showcased its innovative drug delivery technologies to healthcare industry leaders, investors, and potential partners. The event provided a valuable platform to share our innovations, exchange insights with industry professionals, and explore opportunities for future collaboration and commercialization.

We are delighted to have participated in this important healthcare innovation event and look forward to building new connections and partnerships.

Innovative Peptide Therapies Draw VC Interest

PenTide has been invited by HKSTP to the ARENA+ Investment Roadshow for innovative drug development. At the event, PenTide will showcase its advanced nasal peptide therapies, developed using AI and cutting-edge delivery systems, targeting diseases like obesity, Alzheimer’s, and Parkinson’s. The company’s presentation has attracted strong interest from leading venture capitalists.

PenTide received a Silver Medal at the 50th International Exhibition of Inventions Geneva, showcasing its innovative approach and significant potential in using Semaglutide nasal spray for managing obesity and weight.

PenTide is excited to announce that it has been granted a patent in Australia for its new nasal spray formulation of GLP-1 receptor agonists (GLP-1RA). This new method offers a promising alternative to traditional injections for treating diabetes and obesity.

The nasal spray is designed to make it easier for patients to stick to their treatment plans by providing a non-invasive and discreet way to take their medication. This could greatly improve the quality of life for many patients by simplifying their treatment process.

This patent not only highlights PenTide’s commitment to innovative biotechnology but also protects the core technology behind our nasal spray formulation. We believe this development will have a positive impact on both patients and healthcare providers.

PenTide is thrilled to announce it has obtained the Enterprise Support Scheme (ESS) funding to develop its innovative nasal spray formulation of GLP-1 receptor agonists (GLP-1RA). This funding allows PenTide to expedite the research and development of this non-invasive treatment, enhancing patient compliance and quality of life.